Last update 27 Jun 2025

Cal-1 modified CD4+ T lymphocytes

Overview

Basic Info

Drug Type
T-lymphocyte cell therapy
Synonyms-
Target-
Action-
Mechanism
Cell replacements
Therapeutic Areas
NeoplasmsImmune System DiseasesInfectious Diseases+ [3]
Active Indication-
Inactive Indication
AIDS-Related LymphomaHIV InfectionsHodgkin's Lymphoma+ [2]
Originator Organization
Calimmune, Inc.Calimmune, Inc.
Active Organization-
Inactive Organization
Calimmune, Inc.Calimmune, Inc.CSL Behring LLCCSL Behring LLC
License Organization-
Drug Highest PhasePendingPhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Cal-1 modified CD4+ T lymphocytes
NCT01734850
/ CompletedPhase 1/2
An Adaptive Phase I/II Study of the Safety of CD4+ T Lymphocytes and CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct, With and Without Conditioning With Busulfan in HIV-1 Infected Adults Previously Exposed to ART
100 Clinical Results associated with Cal-1 modified CD4+ T lymphocytes
Login to view more data
100 Translational Medicine associated with Cal-1 modified CD4+ T lymphocytes
Login to view more data
100 Patents (Medical) associated with Cal-1 modified CD4+ T lymphocytes
Login to view more data
100 Deals associated with Cal-1 modified CD4+ T lymphocytes
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AIDS-Related LymphomaPhase 2
France
CSL Behring LLCCSL Behring LLC
15 Jan 2019
Hodgkin's LymphomaPhase 2
France
CSL Behring LLCCSL Behring LLC
15 Jan 2019
Plasmablastic LymphomaPhase 2
France
CSL Behring LLCCSL Behring LLC
15 Jan 2019
T-Cell LymphomaPhase 2
France
CSL Behring LLCCSL Behring LLC
15 Jan 2019
HIV InfectionsPhase 2
United States
Calimmune, Inc.Calimmune, Inc.
01 Apr 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT01734850 (CTgov)
Phase 1/2
HIV Infections
13
(Cohort 1 (CSL202 With No Busulfan))
ktisbitdnt = bzyrpbsmpw uaqtfcixkt (dyoxhpbupr, nhddjbqxhz - qporemfrek)
View more
-
06 Aug 2020
(Cohort 2 (CSL202 With 1 Busulfan Dose))
ktisbitdnt = hvucovwbch uaqtfcixkt (dyoxhpbupr, iyjijeprap - vtfoxovbkl)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free